Senores Pharmaceuticals Limited has entered into a loan agreement with Apnar Pharma Private Limited for an inter-corporate loan of up to ₹15 crores.

Loan Agreement Details

The key details of the loan agreement are as follows:

Key Terms and Conditions

The loan agreement includes flexible repayment mechanisms to accommodate both parties' operational requirements. Apnar Pharma is required to repay the loan in one or more tranches upon demand by Senores Pharmaceuticals, with all outstanding amounts becoming immediately due and payable upon such demand.

The borrower has the option to pre-pay the loan amount if mutually agreed between the parties. Interest is calculated following arms-length pricing principles at the specified rate of 10% per annum on the outstanding loan amount.

Purpose and Background

The loan disbursement is intended for a specific corporate purpose, with proceeds to be utilized by Apnar Pharma for discharging and paying off liabilities. This transaction follows a recent share purchase agreement between the two companies.

As of the date of the loan agreement, both parties have confirmed they are not related to each other in any manner.

Regulatory Compliance

Senores Pharmaceuticals has fulfilled its disclosure obligations under the relevant SEBI regulations and circulars. The company has also made the disclosure available on its website at www.senorespharma.com for stakeholder access.

Senores Pharmaceuticals provided comprehensive updates during its recent conference call, addressing strategic revenue positioning, acquisition-related cost implications, and significant revenue projections from its new manufacturing facility.

New Plant Revenue Projections

During the conference call, company management outlined ambitious revenue targets for their new manufacturing plant. The management indicated that in its first year of operation, the new facility could contribute ₹100-120 crores in revenue with an impressive 30% EBITDA margin during the period spanning FY26-27.

Apnar Plant Acquisition Cost Outlook

The pharmaceutical company's management clarified that they do not anticipate any significant increase in operational costs following the Apnar plant acquisition. This guidance provides clarity on the financial impact of the strategic acquisition on the company's cost structure, ensuring operational efficiency remains intact.

Strategic Focus on Regulated Markets

Management also indicated during the conference call that they expect to see a shift in their revenue composition, with regulated markets anticipated to contribute a larger portion of total revenues going forward. This development represents a strategic positioning for the company in markets with stricter regulatory frameworks.

Growth Strategy and Market Positioning

Regulated markets typically refer to regions with stringent pharmaceutical regulations and approval processes, such as the United States, European Union, and other developed markets. These markets generally offer better pricing power and margins compared to semi-regulated or unregulated markets. The combination of new plant capacity and regulated market focus demonstrates the company's commitment to sustainable, profitable growth.

Senores Pharmaceuticals' strategic approach combines capacity expansion through new manufacturing facilities with market positioning in high-value regulated segments, while maintaining strict cost discipline across operations.